Far Infrared Irradiation for Managing, Control and Treatm... | NCT00675077

Studies
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

NCT00675077

Sponsor

GAAD Medical Research Institute Inc.

Status

Unknown status

Last Update Posted

Jan 5, 2009Estimated

Enrollment

5Estimated

Phase

Phase 1

Conditions

Huntington Disease

Interventions

Far Infrared Radiation

Countries

Canada

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2009

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Active, not recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

May 2008

Primary Completion Date

May 2010Estimated

Completion Date

Jun 2010Estimated

First Submitted Date

May 6, 2008

First Submission Date that Met QC Criteria

May 7, 2008

First Posted Date

May 8, 2008Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 2, 2009

Last Update Posted Date

Jan 5, 2009Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Detailed Description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Conditions Module

Conditions

Huntington Disease

Keywords

Akinetic-Rigid Variant of Huntington Disease
Chorea, Chronic Progressive Hereditary (Huntington)
Chronic Progressive Hereditary Chorea (Huntington)
Huntington Chorea
Huntington Chronic Progressive Hereditary Chorea
Huntington Disease, Akinetic-Rigid Variant
Huntington Disease, Juvenile
Huntington Disease, Juvenile-Onset

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

5Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
1	Experimental	Radiation: Far Infrared Radiation (5μm to 20μm wavelength)	Radiation: Far Infrared Radiation

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Far Infrared Radiation	Radiation	Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.	1

Measure	Description	Time Frame
Treatment of people with HD		2 years

Measure	Description	Time Frame
Rehabilitation of people with HD		2 Years

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

People with HD

Exclusion Criteria:

None

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Ken Nedd, M.D.	GAAD Medical Research Institute Inc.	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
The Centre for Incurable Diseases		Toronto	Ontario	M4V 1L5	Canada

Condition Browse Module

MeSH Terms

ID	Term
D006816	Huntington Disease
D002819	Chorea

Ancestor Terms

ID	Term
D001480	Basal Ganglia Diseases
D001927	Brain Diseases
D002493	Central Nervous System Diseases
D009422	Nervous System Diseases

Browse Leaves

Not provided

Browse Branches

Not provided